West Pharmaceutical Hikes 2026 Guidance After 21% Q1 Sales Gain, $1B Buyback
West Pharmaceutical reported Q1 adjusted EPS of $2.13 versus $1.68 consensus and net sales of $844.9 million, a 21% year-over-year increase driven by GLP-1 injectable components. The company raised its full-year 2026 revenue and EPS guidance and authorized a $1 billion share repurchase program.
1. Strong Q1 Financial Results
West Pharmaceutical delivered adjusted EPS of $2.13 in Q1, beating the $1.68 consensus by 27% and generating net sales of $844.9 million, up 21% year-over-year. Organic revenue rose 15.3% across all segments, reflecting broad-based demand.
2. Robust GLP-1 and HVP Component Growth
High-Value Product components grew 23% organically, fueled by surging GLP-1 injectable demand and high-teens expansion in non-GLP-1 biologics and biosimilars. The biologics business delivered 26% organic growth, supported by strong new-launch win rates and easing biosimilar regulations.
3. Upgraded Guidance and $1B Buyback
Strong quarterly results prompted management to raise full-year 2026 revenue and EPS targets. The board also authorized a $1 billion share repurchase program to return capital and support the stock.